U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07883655) titled 'Advanced Multi-omics and -System Approaches to Identify Novel Biomarkers for SMA' on Oct. 09.
Brief Summary: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by mutations in the SMN1 gene, leading to motor neuron degeneration and progressive muscle atrophy. Despite recent advances in therapeutic options, the clinical management of SMA remains challenging due to the heterogeneity of disease progression and variability in treatment response.
This study aims to identify and validate novel biomarkers to improve the diagnosis, prognosis, and therapeutic monitoring of patients with SMA through a multi-omics and...